PCSK9 drug's Ph. III results show potent effects on lipids

Share this article:

Sanofi/Regeneron's highly touted PCSK9 inhibitor, alirocumab, cut LDL "bad" cholesterol by half in the ODYSSEY MONO trial. ODYSSEY MONO is the first study to report data from the 12 Phase III trials that have been initiated so far as part of the more than 23,000 patient ODYSSEY clinical trial program.

In the release, Jay Edelberg, head of the PCSK9 development and launch unit of Sanofi Group said, "We are excited with the findings from the first Phase III trial with alirocumab.  While the majority of our clinical program is investigating alirocumab in combination with lipid-lowering therapies, these monotherapy results are encouraging."
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.